Clinical Trial Update: Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation [Phase 3]

View source ↗

Summary

A Phase III trial of domestic recombinant human follitropin for injection to treat WHO Class II anovulation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anovulation

Drugs mentioned

• recombinant human follitropin for injection (recombinant human follicle-stimulating hormone (rFSH))

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Anovulation | Phase 3 | Status: COMPLETED